Stocks Health care IRD
NASDAQ · Health careOpus Genetics, Inc. (IRD)
Opus Genetics, Inc. brought in $9.9M of revenue over the twelve months to June 30, 2026, down 36.1% from a year earlier. It posted a net loss of $107.6M. At June 30, 2026 it held $88.8M in cash against $35.3M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Key facts about Opus Genetics, Inc.
- Net worth
- Opus Genetics, Inc. has a market value (market cap) of $349.4M at the latest share price, and shareholders' equity of -$13M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $14.2M (+29.1% year on year), with a net loss of $49.6M. Over the 12 months to June 30, 2026: revenue $9.9M, net loss $107.6M.
- Cash flow
- In fiscal 2025 operations used $35.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 6, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Opus Genetics, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Opus Genetics, Inc. does
Opus Genetics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker IRD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $14.2M | -$49.6M | -$0.80 | n/a |
| 2024 | $11M | -$57.5M | -$2.15 | n/a |
| 2023 | $19M | -$10M | -$0.46 | n/a |
| 2022 | $39.9M | $17.9M | $0.87 | n/a |
| 2021 | $589K | -$56.7M | -$3.82 | n/a |
| 2020 | $0 | -$24.6M | -$5.28 | -$6.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where IRD ranks in Health care
Latest SEC filings
What Opus Genetics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 27, 2026Passive stake (5% or more) SCHEDULE 13G
- October 21, 2026
- October 15, 2026
- September 11, 2026
- September 9, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 74% to $755K versus the same quarter last year; diluted EPS -$0.14 versus -$0.12.
Insider trades
What the people running Opus Genetics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $3.2M worth of shares in the last 90 days and bought none on the open market. 6% of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 3, 2026 | Magrath GeorgeChief Executive Officer, Director | Sold | 28,258 | $110.2K |
| October 23, 2026 | Magrath GeorgeChief Executive Officer, Director | Sold | 9,591 | $34.4K |
| October 23, 2026 | Gagnon Robert E.Chief Financial Officer | Soldpre-planned (10b5-1) | 14,000 | $49.6K |
| October 23, 2026 | Yerxa Benjamin RPresident, Director | Sold | 7,669 | $27.2K |
| October 23, 2026 | Yerxa Benjamin RPresident, Director | Sold | 25,520 | $90.1K |
| October 23, 2026 | Schachle Joseph KChief Operating Officer | Sold | 4,767 | $17K |
| September 30, 2026 | Foundation Fighting Blindness Retinal Degeneration FundDirector | Sold | 556,000 | $2.8M |
| September 9, 2026 | Magrath GeorgeChief Executive Officer, Director | Exercised options | 392,157 | $451K |
Who owns IRD
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Perceptive Advisors LLC13G, passive with 2 related filers | 9.99% | August 14, 2026 |
| Adage Capital Management, L.P.13G, passive with 2 related filers | 8.47% | May 13, 2026 |
| Caligan Partners LP13G, passive with 1 related filers | 7.3% | August 14, 2026 |
| Balyasny Asset Management L.P.13G, passive with 4 related filers | 6.64% | August 14, 2026 |
| Nantahala Capital Management, LLC13G, passive with 2 related filers | 6.51% | May 15, 2026 |
| BlackRock, Inc.13G, passive | 6.1% | October 27, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 103 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Nantahala Capital Management, LLC | 6,122,718 | +4,441,388 |
| Caligan Partners LP | 6,077,084 | +2,056 |
| Adage Capital Partners GP, L.L.C. | 6,029,775 | 0 |
| BIOS Capital Management, LP | 3,683,429 | 0 |
| BlackRock, Inc. | 3,116,487 | +2,968,747 |
| Balyasny Asset Management L.P. | 3,087,866 | +369,837 |
| Vanguard Capital Management LLC | 2,958,683 | +508,696 |
| Boxer Capital Management, LLC | 2,815,000 | +565,000 |
| Trails Edge Capital Partners, LP | 2,743,658 | +2,243,658 |
| Millennium Management LLC | 2,302,101 | -328,331 |
| Great Point Partners LLC | 1,970,187 | +1,645,847 |
| Marshall Wace, Llp | 1,945,609 | -367,771 |
| ADAR1 Capital Management, LLC | 1,783,781 | -65,223 |
| Goldman Sachs Group Inc | 1,527,229 | +1,200,420 |
| Woodline Partners LP | 1,434,713 | +80,683 |
| Geode Capital Management, LLC | 1,367,712 | +829,365 |
| Boothbay Fund Management, LLC | 1,189,515 | +402 |
| Opaleye Management Inc. | 1,125,000 | +5,000 |
| SummitTX Capital, L.P. | 1,007,351 | new |
| State Street Corp | 790,136 | +590,183 |
Insiders
14 insiders reported holding 11,940,246 shares in total, about $50.1M at the last price.
| Holder | Shares |
|---|---|
| Foundation Fighting Blindness Retinal Degeneration FundDirector | 3,236,171 |
| Gallagher CamDirector | 2,883,11183,000 held indirectly |
| Magrath GeorgeChief Executive Officer, Director | 2,010,636 |
| Yerxa Benjamin RPresident, Director | 670,917 |
| Gagnon Robert E.Chief Financial Officer | 542,375 |
| Jayagopal AshwathChief Scientific & Dev. Ofc. | 509,233 |
| Rodgers Richard JDirector | 343,022 |
| Ainsworth SeanDirector | 321,692 |
| Manuso James S JDirector | 317,318 |
| Schachle Joseph KChief Operating Officer | 286,673 |
Questions about IRD
What does Opus Genetics, Inc. do?
Opus Genetics, Inc. is a company in the Health care sector, listed on NASDAQ as IRD. Its shares trade on NASDAQ under the ticker IRD.
What is Opus Genetics, Inc.'s net worth?
Opus Genetics, Inc. has a market value (market cap) of $349.4M at the latest share price, and shareholders' equity of -$13M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Opus Genetics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $107.6M on revenue of $9.9M.
How much revenue does Opus Genetics, Inc. make?
Over the twelve months to June 30, 2026 Opus Genetics, Inc. reported revenue of $9.9M. That is 36.1% less than a year earlier.
When did Opus Genetics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from November 5, 2026.
When is Opus Genetics, Inc.'s next earnings report?
Opus Genetics, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare IRD with
Follow IRD
Get an email when Opus Genetics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Opus Genetics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.